Study on the possible use of Vi polysaccharide typhoid fever vaccine to control endemic typhoid fever in Nepal

Asian Pacific Journal of Tropical Disease

Volumn 1, Issue 1, 2011, Pages 76-79

  Karki, Surendra ^a   Kumar, Kuldeep ^b  

^a The Alfred Centre   (Australia)

^b NOVARTIS HEALTHCARE PVT LTD   (India)

Author keywords

Enteric fever; Nepal; Paratyphoid fever; Salmonella paratyphi; Typhoid fever; Vaccine; Vi polysaccharide typhoid fever vaccine

Indexed keywords

TY21A VACCINE; TYPHOID VACCINE; UNCLASSIFIED DRUG;

AGE DISTRIBUTION; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; ENDEMIC DISEASE; HEALTH PROGRAM; HUMAN; INCIDENCE; INFECTION CONTROL; INFECTION RISK; NEPAL; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; SALMONELLA PARATYPHI; SALMONELLA TYPHI; TYPHOID FEVER; VACCINATION;

EID: 84856481060     PISSN: 22221808     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2222-1808(11)60019-4     Document Type: Article

References (28)

1. Edelman R, Levine MM Summary of an international workshop on typhoid fever. Rev Inf Dis 1986, 8:329-349.
2. Crump JA, Luby SP, Mintz ED The global burden of typhoid fever. Bull World Health Organ 2004, 82(5):346-353.
3. Ochiai RL, Acosta CJ, Danovaro-Holliday MC, Baiqing D, Bhattacharya SK, Agtini MD, et al. A study of typhoid fever in five Asian countries: disease burden and implications for control. Bull World Health Organ 2008, 86(4):260-268.
4. Murdoch DR, Woods CW, Zimmerman MD The etiologyof febrile illness in adults presenting to Patan Hospital inKathmandu, Nepal. Am J Trop Med Hyg 2004, 706:670-675.
5. Bhatta DR, Bangtrakulnonth A, Tishyadhigama P, Saroj SD, Bandekar JR, Hendriksen, et al. Serotyping, PCR, phage-typing and antibiotic sensitivity testing of Salmonella serovars isolated from urban drinking water supply systems of Nepal. Lett Appl Microbiol 2007, 44(6):588-594.
6. Lewis MD, Serichantalergs O, Pitarangsi C, Chuanak N, Mason CJ, Regmi, et al. Typhoid fever: a massive, single-point source, multidrug-resistant outbreak in Nepal. Clin Infect Dis 2005, 40(4):554-561.
7. Chau TT, Campbell JI, Galindo CM, Van Minh Hoang N, Diep TS, Nga TT, et al. Antimicrobial drug resistance of Salmonella enterica Serovar Typhi in Asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. Antimicrobial Agents Chemother 2007, 51(12):4315-4323.
8. Pokharel BM, Koirala J, Dahal RK, Mishra SK, Khadga PK, Tuladhar NR Multidrug-resistant and extended-spectrum beta-lactamase (ESBL)-producing Salmonella enterica (serotypes Typhi and Paratyphi A) from blood isolates in Nepal: surveillance of resistance and a search for newer alternatives. Int J Infect Dis 2006, 10(6):434-438.
9. Woods CW, Murdoch DR, Zimmerman MD, Glover WA, Basnyat B, Wolf L, et al. Emergence of Salmonella enterica serotype Paratyphi A as a major cause of enteric fever in Kathmandu, Nepal. Trans R Soc Trop Med Hyg 2006, 100(11):1063-1067.
10. Maskey AP, Day JN, Phung QT, Thwaites GE, Campbell JI, Zimmerman M, et al. Salmonella enterica serovar Paratyphi A and S. enterica serovar Typhi cause indistinguishable clinical syndromes in Kathmandu, Nepal. Clin Infect Dis 2006, 42(9):1247-1253.
11. Maskey AP, Basnyat B, Thwaites GE, Campbell JI, Farrar JJ, Zimmerman MD Emerging trends in enteric fever in Nepal: 9124 cases confirmed by blood culture 1993-2003. Trans R Soc Trop Med Hyg 2008, 102(1):91-95.
12. Pokharel P, Rai SK, Karki G, Katuwal A, Vitrakoti R, Shrestha SK Study of enteric fever and antibiogram of Salmonella isolates at a Teaching Hospital in Kathmandu Valley. Nepal Med Coll J 2009, 11(3):176-178.
13. Prajapati B, Rai GK, Rai SK, Upreti HC, Thapa M, Singh G, et al. Prevalence of Salmonella typhi and paratyphi infection in children: a hospital based study. Nepal Med Coll J 2008, 10(4):238-241.
14. Sharma NP, Peacock SJ, Phumratanaprapin W, Day N, White N, Pukrittayakamee S A hospital-based study of bloodstream infections in febrile patients in Dhulikhel Hospital Kathmandu University Teaching Hospital, Nepal. Southeast Asian J Trop Med Public Health 2006, 37(2):351-356.
15. World Health Organization Typhod vaccine: WHO position paper. Weekly Epidemiol Report 2008, 83:49-60.
16. Garmory HS, Brown KA, Titball RW Salmonella vaccines for use in humans: present and future perspectives. FEMS Microbiol Rev 2002, 26(4):339-353.
17. Acharya IL, Lowe CU, Thapa R, Gurubacharya VL, Shrestha MB, Cadoz M, et al. Prevention of Typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report. N Engl J Med 1987, 317(18):1101-1104.
18. Klugman KP, Koornhof HJ, Robbins JB, Le Cam NN Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine 1996, 14(5):435-438.
19. Sur D, Ochiai RL, Bhattacharya SK, Ganguly NK, Ali M, Manna B, et al. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India. N Engl J Med 2009, 361(4):335-344.
20. Lin FY, Ho VA, Khiem HB, Trach DD, Bay PV, Thanh TC, et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 2001, 344(17):1263-1269.
21. International Vaccine Institute Typhoid fever [Accessed 15th Feb 2010]. http://www.ivi.int/program/tr_domi_Typhoid.html.
22. Cook J, Jeuland M, Whittington D, Poulos C, Clemens J, Sur D, et al. The cost-effectiveness of typhoid Vi vaccination programs: calculations for four urban sites in four Asian countries. Vaccine 2008, 26(50):6305-6316.
23. Whittington D, Sur D, Cook J, Chatterjee S, Maskery B, Lahiri M, et al. Rethinking cholera and typhoid vaccination policies for the poor: Private demand in Kolkata, India. World Development 2009, 37(2):399-409.
24. Global Alliance for Vaccines and Immunization Vaccine investment strategy [Accessed 15th Feb 2010]. http://www.google.no/url?url=http://www.gavialliance.org/resources/WG_retreat_DC_29___30_Sept___FINAL_REPORT.pdf.
25. Agtini MD, Ochiai RL, Soeharno R, Lee HJ, Sundoro J, Hadinegoro SR, et al. Introducing Vi polysaccharide Typhoid fever vaccine to primary school children in North Jakarta, Indonesia, via an existent school-based vaccination platform. Public Health 2006, 120(11):1081-1087.
26. Thiem VD, Danovaro-Holliday MC, Canh do G, Son ND, Hoa NT, Thuy DT, et al. The feasibility of a school-based VI polysaccharide vaccine mass immunization campaign in Hue City, central Vietnam: streamlining a Typhoid fever preventive strategy. Southeast Asian J Trop Med Public Health 2006, 37(3):515-522.
27. Thiem VD, Lin FY, Canh DG, Son NH, Anh DD, Mao ND, et al. Vi conjugate typhoid vaccine (Vi-rEPA) is safe, elicits protective levels of IgG anti-Vi and is compatible with routine infant vaccines. Clin Vaccine Immunol 2011; Mar 16, [Epub ahead of print].
28. Enteric fever caused by Salmonella infections http://www.nibr.com/downloads/research/NVGH/Salmonella-Fact-Sheet.pdf.